louisiana glp-1 nausea class action Weight Loss Drugs Lawsuit Louisiana spent over $1B on

These are also the doses studied and approved for prevention of secondary cardiovascular events and metabolic dysfunction-associated steatotic liver disease (semaglutide) and for sleep apnea (tirzepatide)

Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling

Recent progress of lipid nanoparticles-based lipophilic drug delivery: focus on surface modifications

Recent Updates November 22, 2025: Updated Shed information to include lower prices for premium coaching and the addition of Wegovy and Zepbound to its available treatments

H20052237, produced by Sino-American Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd